Aprecia Pharmaceuticals

Aprecia Pharmaceuticals is the global leader in applying binder jet 3D printing technology to pharmaceutical manufacturing, holding a foundational IP position with 126 granted patents. The company achieved a historic milestone with the FDA approval and commercialization of Spritam, a high-dose, rapidly disintegrating tablet, validating its platform. Operating as a private, revenue-generating company, Aprecia offers end-to-end services from formulation development to commercial-scale cGMP production for partners. Its business model centers on leveraging its proprietary 3DP platform to solve complex drug delivery challenges for the pharmaceutical industry.

Proprietary binder jet 3D printing (ZipDose) platform for creating highly porous, rapidly disintegrating oral dosage forms with precise control over dose, release profiles, and geometry.

Aprecia is the clear first-mover and IP leader in pharmaceutical 3DP, with the only FDA-approved product. Competition exists from academic labs and firms exploring other 3DP methods (e.g., FDM, SLA) for pharmaceuticals, but none have matched Aprecia's regulatory and commercial validation.